

Edward T H Yeh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1525644/publications.pdf>

Version: 2024-02-01

33
papers

5,040
citations

304743

22
h-index

377865

34
g-index

34
all docs

34
docs citations

34
times ranked

6597
citing authors

#	ARTICLE	IF	CITATIONS
1	Impaired Kv7 channel activity in the central amygdala contributes to elevated sympathetic outflow in hypertension. <i>Cardiovascular Research</i> , 2022, 118, 585-596.	3.8	12
2	SENP2-PLC β 24 signaling regulates neurogenesis through the maintenance of calcium homeostasis. <i>Cell Death and Differentiation</i> , 2022, 29, 337-350.	11.2	5
3	PEP-sNASP Peptide Alleviates LPS-Induced Acute Lung Injury Through the TLR4/TRAF6 Axis. <i>Frontiers in Medicine</i> , 2022, 9, 832713.	2.6	3
4	The SUMO-specific protease SENP2 plays an essential role in the regulation of Kv7.2 and Kv7.3 potassium channels. <i>Journal of Biological Chemistry</i> , 2021, 297, 101183.	3.4	5
5	Regulation of TLR4 signaling through the TRAF6/sNASP axis by reversible phosphorylation mediated by CK2 and PP4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	5
6	SUMO: From Bench to Bedside. <i>Physiological Reviews</i> , 2020, 100, 1599-1619.	28.8	155
7	Desumoylase SENP6 maintains osteochondroprogenitor homeostasis by suppressing the p53 pathway. <i>Nature Communications</i> , 2018, 9, 143.	12.8	26
8	Potential of Oncocardiologyâ€™Reply. <i>JAMA Cardiology</i> , 2017, 2, 818.	6.1	1
9	Cancer and Clot. <i>Journal of the American College of Cardiology</i> , 2017, 70, 939-941.	2.8	20
10	Cardiovascular Complications of Cancerâ€™Therapy. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2552-2565.	2.8	221
11	Cardiovascular Complications of Cancerâ€™Therapy. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2536-2551.	2.8	298
12	Withdrawal of Heart Failure Medications in Cancer Survivors With Chemotherapy-Induced Left Ventricular Dysfunction: A Pilot Study. <i>Journal of Cardiac Failure</i> , 2016, 22, 481-482.	1.7	2
13	The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study. <i>Journal of Cardiac Failure</i> , 2016, 22, 433-438.	1.7	68
14	Oncocardiologyâ€™Past, Present, and Future. <i>JAMA Cardiology</i> , 2016, 1, 1066.	6.1	88
15	The Future of Onco-Cardiology. <i>Circulation Research</i> , 2016, 119, 896-899.	4.5	29
16	SUMOylated ORC2 Recruits a Histone Demethylase to Regulate Centromeric Histone Modification and Genomic Stability. <i>Cell Reports</i> , 2016, 15, 147-157.	6.4	36
17	Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond. <i>Canadian Journal of Cardiology</i> , 2016, 32, 863-870.e5.	1.7	62
18	Subclinical Cardiotoxicity Associated Withâ€™Cancer Therapy. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2523-2525.	2.8	20

#	ARTICLE	IF	CITATIONS
19	A Critical SUMO1 Modification of LKB1 Regulates AMPK Activity during Energy Stress. <i>Cell Reports</i> , 2015, 12, 734-742.	6.4	40
20	Induction of SENP1 in myocardium contributes to abnormalities of mitochondria and cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 79, 115-122.	1.9	32
21	An Essential Role of Small Ubiquitin-like Modifier (SUMO)-specific Protease 2 in Myostatin Expression and Myogenesis. <i>Journal of Biological Chemistry</i> , 2014, 289, 3288-3293.	3.4	31
22	Hyper-SUMOylation of the Kv7 Potassium Channel Diminishes the M-Current Leading to Seizures and Sudden Death. <i>Neuron</i> , 2014, 83, 1159-1171.	8.1	86
23	Onco-cardiology: the time has come. <i>Texas Heart Institute Journal</i> , 2011, 38, 246-7.	0.3	21
24	SUMO-Specific Protease 2 Is Essential for Suppression of Polycomb Group Protein-Mediated Gene Silencing during Embryonic Development. <i>Molecular Cell</i> , 2010, 38, 191-201.	9.7	188
25	SUMOylation and De-SUMOylation: Wrestling with Life's Processes. <i>Journal of Biological Chemistry</i> , 2009, 284, 8223-8227.	3.4	402
26	Cardiovascular Complications of Cancer Therapy. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2231-2247.	2.8	1,083
27	Cardiotoxicity Induced by Chemotherapy and Antibody Therapy. <i>Annual Review of Medicine</i> , 2006, 57, 485-498.	12.2	118
28	A novel approach to studying the transformation of human stem cells into cardiac cells in vivo. <i>Canadian Journal of Cardiology</i> , 2006, 22, 66B-71B.	1.7	6
29	High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. <i>Clinical Cardiology</i> , 2005, 28, 408-412.	1.8	78
30	Cardiovascular Complications of Cancer Therapy. <i>Circulation</i> , 2004, 109, 3122-3131.	1.6	692
31	C-reactive protein: The pawn has been promoted to queen. <i>Current Atherosclerosis Reports</i> , 2003, 5, 101-105.	4.8	29
32	Transdifferentiation of Human Peripheral Blood CD34 ⁺ -Enriched Cell Population Into Cardiomyocytes, Endothelial Cells, and Smooth Muscle Cells In Vivo. <i>Circulation</i> , 2003, 108, 2070-2073.	1.6	406
33	Modulation of C-Reactive Protein-Mediated Monocyte Chemoattractant Protein-1 Induction in Human Endothelial Cells by Anti-Atherosclerosis Drugs. <i>Circulation</i> , 2001, 103, 2531-2534.	1.6	767